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Brown and beige adipocytes are potent therapeutic agents to increase energy expen-
diture and reduce risks of obesity and its affiliated metabolic symptoms. One strategy 
to increase beige adipocyte content is through inhibition of the evolutionarily conserved 
Notch signaling pathway. However, systemic delivery of Notch inhibitors is associated 
with off-target effects and multiple dosages of application further faces technical and 
translational challenges. Here, we report the development of a biodegradable poly-
meric microsphere-based drug delivery system for sustained, local release of a Notch 
inhibitor, DBZ. The microsphere-based delivery system was fabricated and optimized 
using an emulsion/solvent evaporation technique to encapsulate DBZ into poly(lac-
tide-co-glycolide) (PLGA), a commonly used biodegradable polymer for controlled drug 
release. Release studies revealed the ability of PLGA microspheres to release DBZ in a 
sustained manner. Co-culture of white adipocytes with and without DBZ-loaded PLGA 
microspheres demonstrated that the released DBZ retained its bioactivity, and effectively 
inhibited Notch and promoted browning of white adipocytes. Injection of these DBZ-
loaded PLGA microspheres into mouse inguinal white adipose tissue depots resulted 
in browning in vivo. Our results provide the encouraging proof-of-principle evidence for 
the application of biodegradable polymers as a controlled release platform for delivery 
of browning factors, and pave the way for development of new translational therapeutic 
strategies for treatment of obesity.
Keywords: notch inhibition, browning, Plga, microspheres, drug delivery, obesity
inTrODUcTiOn
The obesity epidemic has posed a major concern for public health in modern society due to its 
association with a spectrum of metabolic diseases, including type 2 diabetes (T2D), heart diseases, 
hyperglycemia, and multiple cancers (1, 2). Obesity is morphologically characterized by the exces-
sive lipid storage in the white adipose tissue (WAT) and featured as a complex disorder of energy 
imbalance wherein intake outpaces expenditure. Considerable efforts have been devoted to explore 
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the pathological mechanisms as well as the cellular and molecular 
therapeutic targets to combat obesity.
Currently, there are few medications available for obesity 
treatment (3). Mostly, those therapies are dedicated to decreasing 
energy intake by either suppressing appetite through stimulat-
ing the central nervous system or reducing nutrient digestion 
and absorption within the gastrointestinal tract (4). However, 
those medications only produce modest effects and are usually 
accompanied with unpleasant, potentially harmful side effects 
(5). Thus, alternative approaches to overcoming obesity are under 
extensive exploration. One such approach is through boosting 
energy expenditure. Recently, this strategy through stimulating 
thermogenesis has been emerging as an appealing alternative.
Brown adipose tissue (BAT) is the primary site of thermo-
genesis through uncoupling mitochondrial respiration and ATP 
synthesis via uncoupling protein 1 (Ucp1). While producing heat, 
BAT consumes not only free fatty acid but also large amounts 
of glucose (6, 7), thus providing benefits to metabolic health. 
Classical BAT is abundant in neonates but diminishes with age 
leading to limited quantities in adult humans. This compromises 
the therapeutic value of BAT in clinical intervention of obesity.
The recent discovery of inducible BAT (iBAT), also called beige 
adipose tissue, in WAT depots reignites the promise of obesity 
treatment through stimulating energy expenditure (8, 9). Beige 
adipocytes also possess robust thermogenic capacity, which has 
been confirmed recently by the transplantation of an engineered 
beige adipose tissue (10). More importantly, iBAT can be stimu-
lated to burn energy in response to multiple pharmacological 
and genetic manipulations. Various factors have been identified 
to induce the transformation from white to beige adipose tissue 
(termed “browning”) over recent years (11, 12).
We have recently reported that inhibition of the Notch signal-
ing pathway leads to browning of WAT, and thus ameliorates 
obesity (13). Notch signaling is well known to play fundamental 
roles in organ development and cell fate determination, but its 
regulatory roles in energy homeostasis has previously been 
underappreciated. We showed that genetic deletion of Notch1 
receptor or the nuclear mediator of Notch signaling (Rbpj) in 
mice improved their glucose tolerance and insulin sensitivity 
through inducing browning of WAT. Importantly, Notch inhibi-
tion through intraperitoneal injection of dibenzazepine (DBZ), 
a γ-secretase inhibitor, similarly improved insulin sensitivity 
and glucose homeostasis. However, it remains elusive whether 
this systemic administration of DBZ causes any uncontrolled 
drug distribution and potential off-target side effects as Notch 
has been recognized to play multifaceted roles in various types of 
cells (14). Therefore, it is imperative to develop an effective drug 
delivery system to locally and continuously exert effects of Notch 
inhibition specifically on WAT.
Polymer-based drug delivery systems provide a robust tech-
nology platform to enable sustained, spatio-temporally controlled 
drug release (15). Biodegradable polymers are of utmost interest, 
because they can be broken down and excreted or resorbed by the 
body without the necessity for removal interventions or surgical 
procedures (16, 17). Biodegradable polymer microspheres with 
predetermined degradation and drug release profiles have been a 
primary research focus for development of effective drug delivery 
systems for a variety of applications, including cancer, cardio-
vascular diseases, and vaccine development (18, 19). Among a 
variety of polymers that have been employed for drug delivery, 
poly(lactide-co-glycolide) (PLGA), copolymers of lactic acid and 
glycolic acid, have been particularly prominent due to biocom-
patibility, biodegradability, and convenient processability (20). 
PLGA microspheres constitute a versatile class of drug delivery 
vehicles from which the drug release kinetics can be controlled 
by modulating the microsphere size, molecular weight, and 
composition of PLGA (21, 22).
In this study, we aimed to develop a PLGA microsphere-based 
DBZ delivery system to promote browning of WAT for the treat-
ment of obesity (Figure 1). PLGA with a 50:50 lactide to glycolide 
ratio was utilized since this specific polymer has a relatively fast 
degradation rate among the PLGA family, which is advantageous 
to induce browning. We formulated the DBZ-loaded PLGA 
microspheres using an emulsion/solvent evaporation technique 
and characterized the morphology and release profiles of those 
microspheres. Moreover, we demonstrated that the DBZ-loaded 
PLGA microspheres inhibited Notch, and consequently promoted 
browning both in vitro and in vivo. To the best of our knowledge, 
this is the first time that an effective bioengineered system was 
developed to deliver therapeutic agents to convert white adipo-
cytes to beige adipocytes. This study not only contributes to our 
understanding of the underlying mechanism of Notch inhibition 
in the browning process but also paves the way for development 
of novel therapeutic strategies to counteract obesity and its asso-
ciated metabolic syndrome in humans.
MaTerials anD MeThODs
Materials
PLGA (lactide:glycolide 50:50; Mw = 75,000) was obtained from 
lakeshore Biomaterials. Poly(vinyl alcohol) (PVA; 87–90% hydro-
lyzed, average Mw = 30,000–70,000), fluorescein isothiocyanate-
labeled dextran (FITC-dextran) (Mw = 70,000), and DBZ were 
obtained from Sigma. Methylene chloride (DCM), dimethyl 
sulfoxide (DMSO), and acetonitrile were purchased from Fisher 
Scientific.
animals
All the mice used in this study were wild-type lean mice kept 
under normal maintenance in a clean facility at Purdue University. 
All procedures regarding animal maintenance and experimental 
use were conducted following the regulation presented by Purdue 
University’s Animal Care and Use Committee.
FiTc-Dextran-loaded Microsphere 
Formulation and characterization
Fluorescein isothiocyanate-labeled dextran-loaded PLGA micro-
sphere was prepared by a water-in-oil-in-water (WOW) double 
emulsion technique (23). Briefly, 0.4 g of PLGA was dissolved in 
4 mL DCM. Into this organic phase (O), 330 μL of aqueous solution 
(W1) containing ~3.7 mg of FITC-dextran was emulsified using a 
vortex mixer operating at 1,000 rpm for 3 min to form the W1/O 
emulsion. This primary emulsion was injected into 400  mL of 
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an aqueous phase containing 1% (w/v) PVA (W2). The resulting 
W1/O/W2 emulsion was stirred at 400 rpm for overnight with 
an overhead magnetic stirrer to allow solvent evaporation and 
microspheres hardening. The microspheres were then isolated 
by centrifugation, washed three times with distilled water, and 
were dried in a vacuum oven for 24 h. Final products were stored 
in a desiccator. FITC-dextran-loaded PLGA microspheres were 
imaged by fluorescence microscopy (EVOS FL).
DBZ-loaded Microsphere Formulation 
and characterization
PLGA microspheres loaded with DBZ were prepared by an oil-in-
water (O/W) emulsion/solvent evaporation technique (24). The 
oil phase consisted of 540 mg of PLGA and 10.8 mg of DBZ dis-
solved in 2.7 mL DCM. This oil phase was injected into 400 mL of 
an aqueous phase containing 1% (w/v) PVA, which was stirred at 
600 rpm to achieve an O/W emulsion system. The resulting emul-
sion was stirred overnight with an overhead magnetic stirrer to 
allow complete evaporation of the solvent and solidification of the 
droplets into microspheres. The microspheres were then isolated 
by centrifugation, washed three times with distilled water, and 
dried in a vacuum oven for 24 h. Final products were stored in 
a desiccator. The microsphere surface structure was investigated 
by scanning electron microscopy (SEM) (Nova Nano SEM). The 
microsphere diameter was measured using Image-J software, and 
about 130 microspheres were randomly selected for analysis.
The content of DBZ in microspheres was analyzed by a 
precipitation method. Five milligrams of DBZ-loaded PLGA 
microspheres were completely dissolved in chloroform. Once 
dissolved, the chloroform solution was added dropwise into 4 mL 
FigUre 1 | schematic illustration of DBZ-loaded Plga microspheres enabling sustained release of DBZ to induce conversion of white adipocytes 
into beige adipocytes.
of methanol in a centrifuge tube to dissolve DBZ and precipitate 
PLGA. DBZ in the supernatant was collected and concentrated 
under nitrogen stream. Then, DBZ was dried in the vacuum 
oven for overnight and dissolved in 10 mL of 2:1 acetonitrile to 
Millipore water. The product was filtered for high-performance 
liquid chromatography (HPLC) analysis (Thermo HPLC). The 
samples were analyzed using a mobile phase of acetonitrile to 
0.1% phosphoric acid (50:50) at a flow rate of 1  mL/min on a 
pentafluorophenylpropyl column and UV detection at 232 nm. 
Each sample was measured in duplicates. Actual drug loading 
and drug encapsulation efficiency were calculated using the fol-
lowing equations:
 
Theoretical DBZ loading DBZ Total
DBZ Total PLGA
% ( )
( )
%=
+
×100
 
(1.1)
 
Actual DBZ loading DBZ Experiment
DBZ Total PLGA
% ( )
( )
%=
+
×100
 
(1.2)
 
Encapsulation efficiency Actual DBZ loading
Theoretical DB
% =
Z loading
×100%
 
(1.3)
In vitro FiTc-Dextran release from 
Microspheres
Fluorescein isothiocyanate-labeled dextran released from 
microspheres was measured by suspending ~20  mg micro-
spheres in 5 mL PBS buffer at pH 7.4. The samples were placed 
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in a shaker maintained at 37°C and shaken at 200 rpm. At pre-
determined time intervals, the samples were removed from the 
shaker and centrifuged at 1,000 × g for 2 min. Two milliliters of 
medium was aliquoted for analysis and fresh medium of equal 
volume was added thereafter. The precipitated microsphere 
pellets were resuspended in the medium and placed back in 
the shaker. In vitro release of FITC-dextran was studied in trip-
licate. The FITC-dextran concentration in the aqueous phase 
was determined fluorometrically (excitation: 485 nm, emission: 
520 nm, Synergy H1 microplate reader) using a standard cali-
bration curve.
In vitro DBZ release from Microspheres
The DBZ-loaded PLGA microspheres were characterized for 
drug release for 6 days in PBS at pH 7.4 and 37°C. DBZ release 
was measured using HPLC. In brief, 20 mg samples were placed 
in individual centrifuge tubes and filled with 2.5 mL of PBS. The 
samples were then placed in a shaker maintained at 37°C and 
shaken at 200 rpm. At specific time points, 1 mL medium was 
removed, saved for analysis, and replaced with same amount of 
fresh PBS. Time points were chosen such that perfect sink condi-
tions were maintained. Each supernatant sample was extracted 
with 1 mL chloroform. The organic layer was then separated and 
allowed to evaporate. The dried DBZ was then reconstituted with 
1 mL of a 40% solution of acetonitrile in water to provide a suit-
able solution for HPLC analysis (Thermo HPLC).
isolation of Primary Preadipocytes
Primary preadipocytes were collected from limb subcutaneous 
WAT depots and minced into 2–5  mm2 pieces. Then, these 
pieces were subject to 1.5  mg/mL collagenase digestion with 
agitation at 37°C for 1.5–2  h. The digestion was terminated 
with Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal bovine serum (FBS). After that, the floating mature 
adipocytes were removed and the cell suspension was filtered 
through 100  μm mesh, followed by brief centrifugation at 
450 × g for 5 min. The pellet was resuspended and seeded onto 
tissue culture plates.
co-culture of Primary Preadipocytes with 
Microspheres
Primary preadipocytes were cultured in growth medium contain-
ing DMEM, 20% FBS, and 1% penicillin/streptomycin at 37°C 
with 5% CO2. The medium was changed every other day. Upon 
confluence, cells were subject to induction medium containing 
DMEM, 10% FBS, 2.85  μM insulin, 0.3  μM dexamethasone, 
and 0.63 mM 3-isobutyl-methylxanthine for 4 days, followed by 
differentiation medium containing DMEM, 200 nM insulin, and 
10  nM triiodothyronine for four more days. Meanwhile, 5  mg 
polymer microspheres were added in permeable transwell inserts 
suspended in each well of 24-well plates while cells were induced 
for adipogenic differentiation. Other parallel treatment groups 
included cells in DBZ-containing medium (10 μM) and cells in 
DMSO vehicle control. To monitor adipogenic differentiation, 
the lipid droplets and nuclei of adipocytes during culture were 
counterstained with BODIPY and DAPI, respectively.
Quantitative Polymerase chain reaction
Total RNA was extracted from cell culture through Trizol. Random 
hexamer primers were utilized for the reverse transcription to 
synthesize cDNA. The quantitative polymerase chain reaction 
(qPCR) was performed with a Roche Light Cycler 96 machine 
(Roche). The 18S rRNA was applied as an internal control for 
normalization. For qPCR result analysis, the 2−ΔΔct method was 
used to calculate the fold change.
Protein extraction and Western Blots 
analysis
Total protein was extracted from cells or tissue samples using 
RIPA buffer containing 50  mM Tris–HCl (pH 8.0), 150  mM 
NaCl, 1% Non-idet P-40, 0.5% sodium deoxycholate, and 0.1% 
sodium dodecyl sulfate (SDS). Protein concentrations were 
measured by using Pierce BCA protein assay reagent (Pierce 
Biotechnology, Rockford, IL, USA). Proteins were separated 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
then transferred to polyvinylidene fluoride (PVDF) membranes 
(Millipore Corp., Billerica, MA, USA). Membranes were blocked 
in 5% milk for 1  h and incubated with primary antibodies at 
4°C overnight. The PGC1-α (sc-13067) and GAPDH (sc-32233) 
antibodies were purchased from Santa Cruz Biotechnology, and 
both were diluted 1:1,000. The horseradish peroxidase (HRP)-
conjugated secondary antibody (anti-rabbit IgG, 7074S, Cell 
Signaling) was diluted 1:5,000. Signals were detected with a 
ChemiDoc™ Touch Imaging System (Bio-Rad). The lanes were 
analyzed for densitometry quantification with Bio-Rad Image 
Lab V5.2.1.
In vivo injection of Plga Microspheres
Mice were first anesthetized by a ketamine–xylazine cocktail 
and then either FITC-dextran-loaded PLGA microspheres or 
DBZ-loaded PLGA microspheres (20 mg/30 g body weight) were 
injected into the inguinal WAT depot in one side of the body in 
a 1 mL solution of 0.5% Methocel E4M (wt/vol; Dow Chemical) 
and 0.1% Tween-80 (wt/vol; Sigma) in water. Similarly, PLGA 
microspheres were injected into the contralateral inguinal WAT 
depot. Adipose tissues were harvested after 24  h and 14  days 
post-injection for the study with FITC-dextran-loaded PLGA 
microspheres and DBZ-loaded PLGA microspheres, respectively. 
Oil Red O staining was performed to label the adipocytes for the 
study with FITC-dextran-loaded PLGA microspheres whereas 
hematoxylin and eosin (H&E) and immunohistochemistry 
staining was conducted for the study with DBZ-loaded PLGA 
microspheres.
h&e and immunohistochemistry staining
Adipose tissues were fixed in 10% formalin for 24 h at room tem-
perature. Then, the tissues were embedded into paraffin and cut 
into 4 μm thick slices, deparaffinized, and rehydrated using xylene, 
ethanol, and water by standard methods. Immunohistochemistry 
was performed on a Dako Autostainer (Dako). Slides were incu-
bated with 3% hydrogen peroxide and 2.5% normal horse serum 
(S-2012, Vector), followed by incubation with rabbit polyclonal 
anti-Ucp1 primary antibody diluted 1:200 in 2.5% normal horse 
FigUre 2 | characterization of FiTc-dextran and DBZ-loaded Plga microspheres. (a) Fluorescent image of FITC-dextran-loaded microsphere. Scale bar, 
200 μm. (B) SEM image of a population of DBZ-loaded PLGA microspheres. Scale bar, 400 μm. (c) Higher magnification SEM image of a single DBZ-loaded PLGA 
microsphere. Scale bar, 50 μm. (D) Size distribution of DBZ-loaded PLGA microspheres.
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serum (S-2012, Vector) for 60 min. Signals were detected with 
an anti-rabbit IgG Polymer Detection Kit (MP-7401, Vector). 
Labeling was visualized with 3,3′-diaminobenzidine (DAB) as 
the chromogen (SK-4105, Vector). Slides were counterstained 
with Harris hematoxylin (EK Industries), and whole-slide digital 
images were collected with an Aperio Scan Scope slide scanner 
(Aperio).
statistical analysis
Quantitative data were reported as mean ± SEM P-values were 
calculated by a two-tailed Student’s t-test. P < 0.05 was considered 
to be statistically significant.
resUlTs
Formulation and characterization of Plga 
Microspheres
Using PLGA 50:50, drug-loaded PLGA microspheres were pre-
pared and characterized for drug distribution and morphological 
characteristics. We first encapsulated FITC-dextran, a commonly 
used fluorescent probe, into PLGA microspheres to assess the 
distribution of FITC-dextran in microspheres by fluorescent 
microscopy. It was observed that green fluorescence was uniformly 
distributed throughout the microspheres (Figure 2A). Next, we 
formulated DBZ-loaded PLGA microspheres by optimizing the 
process parameters, such as PVA concentration and stirring 
speed, to obtain a narrow microsphere size range of 50–150 μm 
(Figure 2B). Higher magnification SEM micrograph revealed the 
smooth surface morphology of the microsphere (Figure 2C). The 
size distribution of the DBZ-loaded PLGA microspheres resem-
bled a Gaussian distribution with more than 50% in the range 
of 90–110 μm (Figure 2D). The actual DBZ loading percentage 
was characterized to be ~1.4% (w/w), equivalent to ~68% DBZ 
encapsulation efficiency.
Plga Microsphere system enables  
FiTc-Dextran and DBZ release
To examine the cargo drug release capabilities from the PLGA 
microspheres, we first placed the FITC-dextran-loaded PLGA 
microspheres in the PBS at 37°C and release was quantified 
fluorometrically. The FITC-dextran-loaded PLGA microspheres 
showed a rapid release profile, which resulted in about 50% 
of total FITC-dextran released after 24  h (Figure  3A). This is 
presumably due to the hydrophilic nature of the FITC-dextran. 
We further characterized the release profile of DBZ from DBZ-
loaded PLGA microspheres (Figure 3B). In general, the release 
FigUre 3 | In vitro release profiles of FiTc-dextran and DBZ from 
Plga microspheres. (a) In vitro release of FITC-dextran from microspheres 
in PBS at pH 7.4 and 37°C. (B) In vitro release of DBZ from microspheres in 
PBS at pH 7.4 and 37°C.
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rate of DBZ from PLGA microspheres was much slower than 
that of FITC-dextran. Approximately, 2% DBZ was released from 
PLGA microspheres in the first 24 h. And the release rate became 
significantly decreased thereafter and around 3% DBZ (~8 μg) 
was released over 6  days, indicating that DBZ can be released 
from PLGA in a sustained manner.
DBZ-loaded Plga Microspheres Promote 
Browning in adipocytes
As the initial attempt to test the bioactivity of DBZ released 
from PLGA microspheres, we co-cultured DBZ-loaded PLGA 
microspheres with primary adipocytes and examined the cel-
lular responses (Figure 4A). Following induction of adipogenic 
differentiation for 8  days, we observed classical lipid droplets 
characterized by the BODIPY immunofluorescence (Figure 4A), 
which suggested that microspheres did not cause obvious adverse 
effects on cell culture. Then, we continued to analyze the mRNA 
levels of Notch target and thermogenic genes. As we expected, 
DBZ-loaded PLGA microspheres significantly inhibited Notch, 
demonstrated by the 40% mRNA reduction of Notch target genes, 
Hes1 and HeyL (Figure  4B). Importantly, DBZ-loaded PLGA 
microspheres dramatically increased mRNA levels of browning 
markers, including Ucp1, Cidea, and Ppargc1a (Figure  4C), as 
well as mitochondria genes, including Cox5b, Cox7a, Cpt1a, and 
Cpt2 (Figure  4D), suggesting that DBZ released from PLGA 
microspheres can inhibit the Notch pathway and consequently 
promote browning. In addition, western blot results shown in 
Figure 4E demonstrated that DBZ-loaded PLGA microspheres 
significantly elevated the protein level of Pgc1-α (encoded by 
Ppargc1a) by around 3.5-fold (Figure 4F), which plays key roles in 
mitochondrial biogenesis and oxidative metabolism. Collectively, 
all these data confirmed that DBZ remained bioactive to induce 
browning after being released from PLGA microspheres in vitro.
DBZ-loaded Plga Microspheres 
stimulate Browning In vivo
To further test whether PLGA microspheres can locally deliver 
DBZ and promote browning in vivo, we sought to directly inject 
microspheres to the mouse inguinal WAT depots and assess the 
browning effect thereafter (Figure  5A). Initially, to ensure that 
microspheres could be precisely injected into the depots, we uti-
lized the FITC-dextran-loaded microspheres to track microsphere 
placement. The microsphere injection sites were readily identified 
with green fluorescence via gross observation in the target inguinal 
adipose tissues (Figure 5B). Following 24 h of injection, FITC-
dextran-loaded microspheres maintained round morphologies 
with expanded fluorescence, indicating the release of FITC-dextran 
from the microspheres over this time period (Figures  5C,D). 
This observation was also in agreement with our previous results 
regarding the release profile of FITC-dextran in vitro.
We next injected DBZ-loaded PLGA microspheres into the 
inguinal WAT depots using the same procedure. Fourteen days 
after injection, the inguinal WAT was collected and processed for 
paraffin embedding and sectioning. Through H&E staining, we 
observed that DBZ-loaded PLGA microspheres were dispersed 
within the WAT and maintained round morphologies in the 
size range of 50–150 μm. Importantly, these microspheres did 
not elicit any significant inflammatory responses (Figure  6A). 
Of note, DBZ-loaded PLGA microspheres drastically decreased 
the sizes of mature white adipocytes (Figure  6B), a hallmark 
indicator of browning effect. Multilocular Ucp1+ beige adipocytes 
were evidently abundant with DBZ-loaded PLGA microspheres 
(Figure 6B). Also, this morphological feature of browning was 
further supported by western blot of tissue samples exhibiting 
increased protein levels of Pgc1-α and Ucp1 in the DBZ-loaded 
microsphere group compared to control (Figure 6C). All these 
data demonstrated that DBZ was successfully released from 
microspheres and retained its biological activity of Notch inhibi-
tion to promote browning in vivo.
DiscUssiOn
There is accumulating evidence that significant metabolic 
differences that distinguish beige adipocytes from white adi-
pocytes can potentially be successfully exploited to establish 
FigUre 4 | DBZ-loaded Plga microspheres inhibit notch and promote browning in vitro. (a) Diagram of the co-culture system with primary white 
adipocytes seeded on well bottom and DBZ-loaded microspheres placed within a permeable insert. Mature adipocytes were labeled with BODIPY (red). Nuclei were 
counterstained with DAPI (green). Expression of (B) Notch target genes, (c) browning markers, and (D) mitochondria genes in white adipocytes co-cultured with 
DBZ-loaded PLGA microspheres. (e) Protein levels of Pgc1-α in white adipocytes co-cultured with DBZ-loaded PLGA microspheres. (F) Quantification of protein 
level for Pgc1-α relative to Gapdh. DBZ: cells in DBZ-containing medium (10 μM); CTRL: cells treated with DMSO vehicle control. N = 3. *P < 0.05, **P < 0.01.
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new therapeutic strategies for treatment and/or prevention of 
obesity. Thus, identifying and targeting mechanisms underlying 
browning is crucial in the development of effective therapeutics 
to reduce adiposity. The Notch signaling pathway is important 
for cell–cell communication and cell fate determination during 
development and is required for adult tissue homeostasis. Notch 
target gene Hairy/enhancer-of-split 1 (Hes1) inhibits the tran-
scriptions of PR domain-containing 16 (Prdm16), peroxisome 
proliferator-activated receptor gamma (Pparγ) coactivator 1 
alpha (Ppargc1a) and Pparγ, all critical in the brown adipocyte 
biogenesis (13). This leads to reduced mitochondrion numbers 
and expression of Ucp1 (25–27). Notably, inhibition of Notch 
signaling through intraperitoneal injection of DBZ has been 
found to induce browning of white adipocytes, and consequently 
reduced obesity and improved glucose balance in obese mice (13). 
This strategy has been proposed to open up another novel avenue 
to treat obesity and its associated metabolic diseases. However, 
potential compliance issues associated with a requirement for 
multiple periodic drug injections, in combination with safety and 
efficacy concerns over widespread drug distribution in the body 
reduce the translational potential of this treatment. For instance, 
Notch inhibition has been proposed to affect multiple biological 
processes, such as angiogenesis (28, 29), bone formation (30, 31), 
and myogenesis (32, 33). Therefore, it would be beneficial if a 
carrier system were capable of delivering DBZ locally to the WAT 
in a sustained manner for treatment of obesity.
FigUre 5 | characterization of FiTc-dextran-loaded microspheres following injection into mice. (a) Direct injection of microspheres into inguinal adipose 
depot of WT mice. (B) Injected microspheres (blue arrow) identified through gross observation of inguinal adipose tissues. (c) Fluorescent image illustrating the 
distribution of microspheres after 24 h of injection. (D) Representative image showing green fluorescence from FITC-dextran-loaded microspheres dispersed in white 
adipocytes labeled by Oil Red O staining. Green: FITC; Red: Oil Red O.
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Polymer-based controlled drug delivery systems offer several 
unique advantages over conventional drug delivery including 
continuous drug release, decreased systemic side effects, and 
increased patient compliance (15). Polymer degradation is highly 
desirable in controlled drug delivery because it eliminates the need 
for the surgical removal of implants. PLGA is known to degrade 
by simple hydrolysis of the ester bonds into lactic and glycolic 
acids, which are ultimately metabolized to carbon dioxide and 
water (34). PLGA microspheres have been extensively investi-
gated as carriers to deliver a variety of therapeutic agents (21, 22). 
The release of an encapsulated agent from PLGA microspheres 
is controlled by both diffusion and polymer degradation. The 
drug release kinetics can be tailored by varying the copolymer 
composition, molecular weight, and microsphere size (20–22). In 
particular, the degradation rate of PLGA depends on the copoly-
mer composition. The molecular weight loss during hydrolysis is 
accelerated with an increase in glycolide content. This is attributed 
to greater absorption of water into the polymer matrix. For exam-
ple, PLGA exhibited a degradation time in the order of PLGA 
50:50 (1–2 months) < PLGA 75:25 (4–5 months) < PLGA 85:15 
(5–6 months) (35). Polymers with higher molecular weight result 
in slower degradation rates (36). Furthermore, the size of PLGA 
microspheres is an important controlling factor on drug diffusion 
and polymer degradation. Berchane et al. demonstrated that the 
initial burst release rate of piroxicam from PLGA microspheres 
decreased with an increase in microsphere size from 13.9 to 
81.2 μm, which is consistent with Fick’s law of diffusion because 
an increase of diffusion pathways would reduce the drug release 
rate (37). It has been reported that large microspheres degrade in 
a heterogeneous manner wherein the degradation rate in the core 
is greater than that at the surface (38). In contrast, microspheres 
with diameter <300 μm undergo a homogeneous degradation 
whereby the core degradation rate is equivalent to the surface 
one (39). Small microspheres also degrade slower than large 
microspheres resulting from a decreased accumulation of acidic 
degradation products (40). In vitro release studies showed that 
the fabricated DBZ-loaded PLGA microspheres in the size range 
of 50–150 μm enabled sustained release of DBZ resulting in ~3% 
of encapsulated drug released over 6 days. This gradual release 
will be particularly beneficial to circumvent the need for multiple 
periodic injections of DBZ for induction of browning.
Co-culture of primary preadipocytes with DBZ-loaded 
PLGA microspheres demonstrated that released DBZ retained 
its bioactivity and effectively inhibited Notch signaling and 
upregulated expression of brown fat specific genes (Figure  4). 
For example, the expression of Notch downstream targets Hes1 
and HeyL in cultured white adipocytes with both DBZ and DBZ-
loaded microspheres were reduced by more than 40%, indicating 
the bioactivity of DBZ released from polymers. Furthermore, 
DBZ-loaded microspheres resulted in an elevated expression 
of browning markers, including Ucp1, Cidea, and Ppargc1a, as 
well as mitochondria genes, including Cox5b, Cox7a, Cpt1a, 
and Cpt2. Notably, brown and beige adipocytes contain more 
mitochondria than white adipocytes, and possess ability to 
FigUre 6 | DBZ-loaded Plga microspheres induce browning in vivo. 
(a) H&E staining showing DBZ-loaded PLGA microspheres (yellow 
arrowhead) dispersed within the WAT depot. Scale bar, 200 μm. (B) H&E 
(top) and UCP1 (bottom) staining of inguinal WAT from mice at 14 days 
post-injection of DBZ-loaded PLGA microspheres. Scale bars, 100 μm. (c) 
Protein levels of Pgc1-α and Ucp1 of inguinal WAT from mice at 14 days 
post-injection of DBZ-loaded PLGA microspheres.
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burn lipids (through β-oxidation) to generate heat (11). Pgc1-α 
(encoded by Ppargc1a) is also known to induce the expression 
of Ucp1 and other thermogenic components in adipocytes (26, 
41). Our results are also in line with our earlier findings with 
the use of DBZ on browning of white adipocytes (13). The more 
pronounced increase in Ucp1 and Cidea mRNA levels in the 
PLGA-DBZ-treated groups compared to the DBZ alone groups 
is presumably due to the continued release of DBZ from micro-
spheres, which should have improved the biological activity of 
DBZ and thus highlights a major advantage of our drug delivery 
system for inductive browning.
One of the most important requirements for developing effec-
tive polymer-based drug delivery systems is tissue compatibility. 
PLGA polymers are considered a standard for drug delivery due 
to their recognized biocompatibility and approval by the Food 
and Drug Administration for a number of clinical applications 
(16, 17). The DBZ-loaded PLGA microspheres were well toler-
ated following in vivo injection into the WAT depots (Figure 6A). 
More importantly, we demonstrated that local DBZ-loaded 
microsphere injection successfully induced browning of WAT 
after 14  days (Figures  6B,C). The resultant browning further 
validates that Notch signaling plays a role in regulating the plas-
ticity of white and beige adipocytes in vivo (13).
White adipose tissue is the primary site of long-term energy 
storage. In response to excess calorie intake, the size of the WAT 
expands through hyperplasia and hypertrophy of adipocytes. Our 
work pinpointed the potential of polymeric microspheres as a car-
rier platform to locally deliver DBZ to WAT in a sustained manner. 
Such a localized delivery system may eliminate the need for repeated 
injections as well as potential side effects that are accompanied 
with systemic administration of DBZ. Improved understanding of 
brown and beige adipocyte biology has led to recent discoveries of 
a variety of factors to promote WAT browning, such as fibroblast 
growth factors (42–44), bone morphogenetic proteins (BMPs) 
(45, 46), Irisin (47), T3 and T4 thyroid hormones (45, 46), natriu-
retic peptides (48), and β3-adrenergic pathway agonist (49–51). 
However, as with DBZ, there exist significant safety and efficacy 
concerns on systemic administration of these browning factors as 
uncontrolled tissue exposure may lead to potential off-target side 
effects and unpredictable kinetics. For instance, administration of 
FGF21 is associated with systemic side effects on bone loss (52). 
Therefore, development of effective browning-based therapeutics 
to address the ever-worsening obesity epidemic necessitates the 
integration of advances in controlled release technologies with 
discoveries in beige/brown fat cell biology.
cOnclUsiOn
DBZ-loaded PLGA microspheres with a size range of 50–150 μm 
were prepared as a DBZ delivery system using an emulsion/solvent 
evaporation technique. The DBZ-loaded PLGA microspheres 
supported release of DBZ in a sustained manner. The effective-
ness of DBZ-loaded PLGA microspheres to induce browning 
was demonstrated by both in vitro and in vivo studies. This study 
for the first time demonstrates the feasibility of developing a 
bioengineered carrier system for controlled delivery of DBZ 
to achieve inductive browning using biodegradable polymeric 
microspheres. To facilitate the translation of our technology 
platform to have a positive impact in the therapeutic treatment, 
future efforts will be focused on the evaluation of this controlled 
delivery system with human cells and tissues.
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